Observation for Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to deepen understanding of small cell lung cancer (SCLC) by observing patients already receiving standard treatments. Researchers will collect and analyze tissue and blood samples to identify specific markers that might explain cancer behavior or treatment response. The goal is to gather detailed information to improve future SCLC care. Individuals recently diagnosed with extensive-stage SCLC (stage IV) and beginning a specific chemotherapy and immunotherapy combination are well-suited for this trial. As an unphased trial, it offers patients the opportunity to contribute to research that could enhance future understanding and treatment of SCLC.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems you can continue your standard care therapy while participating.
Why are researchers excited about this trial?
Researchers are excited about this trial because it focuses on observing small cell lung cancer (SCLC) at the extensive stage to gather comprehensive data. Unlike treatments that involve chemotherapy or immunotherapy, this observational study aims to understand the disease better by examining tissue samples from the primary lung tumor or metastatic sites. By analyzing these samples, the study hopes to uncover insights into the biology of SCLC that could lead to more effective treatment strategies in the future.
Who Is on the Research Team?
Virginia Rhodes, MD
Principal Investigator
Tempus AI, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Diagnostic Profiling
Participants undergo diagnostic tumor tissue and plasma ctDNA biomarker profiling
Post-progression Profiling
Participants receive post-progression tumor tissue profiling where possible
Follow-up
Participants are monitored for progression free survival and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- Observation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Tempus AI
Lead Sponsor
Tempus Labs
Lead Sponsor
AstraZeneca
Industry Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from École nationale vétérinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology